US FDA approves Jazz Pharma's therapy for lung cancer
02/10/2025 20:35
Oct 2 (Reuters) - The U.S. Food and Drug Administration on Thursday has expanded the approval for Jazz Pharmaceuticals' JAZZ.O therapy as a maintenance treatment of adult patients with a type of lung cancer. (Reporting by Siddhi Mahatole in Bengaluru; Editing by Sahal Muhammed) ((siddhi.mahatole@thomsonreuters.com;))
Recent news on Jazz Pharmaceuticals
See all newsBrief: Jazz Pharmaceuticals Enters Amendment No. 4 To Credit Agreement On Sept 23, 2026
U.S. STOCKS ON THE MOVE-BWX Technologies, Synopsys,Burlington Stores
U.S. STOCKS ON THE MOVE-Jazz Pharmaceuticals, Celularity, Infleqtion
Jazz Pharma dips after upsized $1.1 bln convertible offering
Brief: Jazz Pharmaceuticals Announces Private Offering Of $1.0 Billion Of Exchangeable Senior Notes Due 2032